Bioequivalence Study Optimization
Design FDA/EMA-compliant bioequivalence study protocols with optimized sample sizes
What You Can Do
This skill helps you design scientifically rigorous and regulatory-compliant bioequivalence study protocols in a fraction of the time. Claude analyzes FDA and ICH guidance documents to extract all applicable requirements, calculates statistically powered sample sizes for your specific formulation and study design, and generates protocol drafts structured for regulatory review. You'll identify compliance gaps, risk mitigate protocol weaknesses, and accelerate CRO handoff with submission-ready documentation.
Features
Systematically extract and cross-reference FDA/ICH BE requirements specific to your formulation type (immediate-release, extended-release, modified-release)
Generate scientifically sound protocol drafts pre-aligned to regulatory expectations with all required sections and justifications
Calculate sample sizes, evaluate crossover design options, and justify statistical assumptions based on pharmacokinetic parameters
Evaluate biowaiver eligibility versus full BE study need based on solubility, permeability, and dissolution data
Detect protocol gaps, missing justifications, and compliance issues before CRO submission to reduce iteration cycles
Cross-reference similar approved BE studies and products to anticipate reviewer questions and strengthen defensibility
Structure age, renal/hepatic impairment, food effect, and DDI study rationale aligned to guidance
Generate chemistry/manufacturing controls references and bioanalytical method validation links for integrated regulatory packages
Example Output
Example 1: Extended-Release Formulation Protocol Outline
Study Design Section Generated:
- Randomized, two-way crossover, single-dose design
- Sample size: n=32 (calculated for 90% power, CV=28% based on literature, BE limits 80-125%)
- Washout period: 14 days (≥5 half-lives per FDA guidance for this BCS II compound)
- Food effect: Fed state per FDA Extended-Release guidance
- Justification: Previous fed/fasted crossover data supports fed as worst case
Example 2: Biowaiver Decision Support
Claude analyzes your dissolution, BCS classification, and P-gp substrate data to recommend: "Full BE study required. While your compound meets BCS Class II criteria (low solubility, high permeability), dissolution shows pH-dependent profiles across GI pH range. FDA precedent for similar ER products (cites 2 reference products) requires in vivo BE despite biowaiver-eligible BCS classification."
Example 3: Statistical Power Calculation Output
For your proposed n=24 crossover design:
- Power = 87% (below 90% target)
- Recommendation: Increase to n=28 to achieve 91% power
- Sensitivity analysis provided: accounts for anticipated CV=26-30% range based on intra-subject variability literature
What's Included
- SKILL.md instruction file: Complete skill setup and usage context
- BE Protocol Template: Structured sections (objectives, endpoints, study design, statistical analysis plan, safety monitoring)
- Sample Size Calculator Worksheet: Pre-formatted spreadsheet with FDA BE parameters and crossover design options
- FDA/EMA Guidance Checklist: Mapped compliance requirements by formulation type (IR, ER, MR, special populations)
- Biowaiver Decision Framework: BCS classification assessment tool and regulatory pathway selection logic
- Risk Assessment Template: Protocol gap identification checklist and compliance validation matrix
Who It's For
- Bioequivalence Study Managers — Designing protocols and managing CRO timelines
- Bioanalytical Scientists — Structuring method validation strategies within BE study designs
- Regulatory Affairs Specialists — Anticipating FDA/EMA questions and ensuring submission readiness
- Formulation Scientists — Evaluating BE pathway decisions (biowaiver vs. full study) for new products
- Clinical Research Organization Partners — Preparing protocol briefing documents and compliance assessments
Best For
- New NDA/ANDA bioequivalence protocol development
- Complex formulation BE designs (extended-release, modified-release, special populations)
- Biowaiver feasibility assessment and regulatory pathway selection
- Sample size justification and statistical power optimization
- FDA/EMA guidance compliance gap analysis and risk mitigation
You might also like
This skill systematically analyzes your product designs to identify manufacturability issues early, saving costly revisions and manufacturing delays. It evaluates geometry, material selection, tolerances, assembly feasibility, and production process constraints. You get actionable feedback on cost drivers, process risks, and design optimizations before committing to production.
by kody-w
This skill organizes complex toxicology datasets, clinical adverse events, and mechanistic findings into structured, FDA/EMA-compliant safety narratives. You input raw safety data—adverse event summaries, laboratory results, animal study findings, vital signs—and receive draft safety summaries, detailed safety assessments, and expedited safety reports ready for regulatory submission. It handles IND applications, annual safety updates, clinical development safety overviews, and urgent safety communications with proper MedDRA coding and regulatory formatting.
by kody-w
You can submit tool designs—drawings, specifications, or descriptions—and Claude will evaluate manufacturability constraints, identify potential failure modes using structured frameworks, and recommend cost-reduction opportunities. You'll receive a prioritized report covering structural analysis, production feasibility, material efficiency, and design trade-offs.
by kody-w
You can take unstructured monitoring visit observations and convert them into formal, audit-ready reports that categorize findings by risk level (Critical, Major, Minor), validate protocol compliance, and generate actionable follow-up items with assigned owners and resolution dates. The skill ensures your documentation meets FDA inspection standards and ICH-GCP requirements while creating clear escalation pathways for high-risk issues.
by kody-w
You can automate the validation of clinical trial data against protocol specifications, identify discrepancies including missing values, out-of-range results, protocol violations, and CRF inconsistencies. The skill generates audit-ready query documentation, categorizes anomalies by severity and type, resolves root causes systematically, and produces FDA inspection-ready reports that trace every data decision and corrective action for CDISC and regulatory submission.
by kody-w
You can submit raw mass spectrometry observations, instrument parameters, or sample preparation details to Claude and receive targeted diagnostic frameworks that explain anomalous results. Claude systematically generates plausible mechanistic explanations for unexpected protein abundance patterns, quantification inconsistencies, and PTM findings—then helps you design minimal, hypothesis-driven troubleshooting experiments to test them.
by kody-wThis skill interprets your FEA simulation results and extracts actionable design improvements. You can pinpoint stress concentrations, validate designs against safety factors and material limits, and receive specific geometry recommendations to reduce weight or improve performance. By automating FEA post-processing, you compress design iteration cycles and make engineering decisions faster.
by kody-w
You can analyze equipment sensors, operational logs, and historical maintenance data to predict failures weeks in advance. Claude generates actionable maintenance schedules, identifies high-risk assets, and calculates the financial impact of preventive vs. reactive maintenance. This skill transforms raw operational data into strategic maintenance decisions that minimize downtime and extend asset life.
by kody-w